22 U.S.C. § 7634 — Malaria response Coordinator

Page 1989 TITLE 22—FOREIGN RELATIONS AND INTERCOURSE § 7634 § 7634. Malaria response Coordinator (a) In general There is established within the United States Agency for International Development a Coordi- nator of United States Government Activities to Combat Malaria Globally (referred to in this section as the ‘‘Malaria Coordinator’’), who shall be appointed by the President. (b) Authorities The Malaria Coordinator, acting through non- governmental organizations (including faith- based and community-based organizations), partner country finance, health, and other rel- evant ministries, and relevant executive branch agencies as may be necessary and appropriate to carry out this section, is authorized to— (1) operate internationally to carry out pre- vention, care, treatment, support, capacity de- velopment, and other activities to reduce the prevalence, mortality, and incidence of ma- laria; (2) provide grants to, and enter into con- tracts and cooperative agreements with, non- governmental organizations (including faith- based organizations) to carry out this section; and (3) transfer and allocate executive branch agency funds that have been appropriated for the purposes described in paragraphs (1) and (2). (c) Duties (1) In general The Malaria Coordinator has primary re- sponsibility for the oversight and coordination of all resources and international activities of the United States Government relating to ef- forts to combat malaria. (2) Specific duties The Malaria Coordinator shall— (A) facilitate program and policy coordina- tion of antimalarial efforts among relevant executive branch agencies and nongovern- mental organizations by auditing, moni- toring, and evaluating such programs; (B) ensure that each relevant executive branch agency undertakes antimalarial pro- grams primarily in those areas in which the agency has the greatest expertise, technical capability, and potential for success; (C) coordinate relevant executive branch agency activities in the field of malaria pre- vention and treatment; (D) coordinate planning, implementation, and evaluation with the Global AIDS Coordi- nator in countries in which both programs have a significant presence; (E) coordinate with national governments, international agencies, civil society, and the private sector; and (F) establish due diligence criteria for all recipients of funds appropriated by the Fed- eral Government for malaria assistance. (d) Assistance for the World Health Organization In carrying out this section, the President may provide financial assistance to the Roll Back Malaria Partnership of the World Health Organization to improve the capacity of coun- tries with high rates of malaria and other af- fected countries to implement comprehensive malaria control programs. (e) Coordination of assistance efforts In carrying out this section and in accordance with section 2151b–4 of this title, the Malaria Co- ordinator shall coordinate the provision of as- sistance by working with— (1) relevant executive branch agencies, in- cluding— (A) the Department of State (including the Office of the Global AIDS Coordinator); (B) the Department of Health and Human Services; (C) the Department of Defense; and (D) the Office of the United States Trade Representative; (2) relevant multilateral institutions, in- cluding— (A) the World Health Organization; (B) the United Nations Children’s Fund; (C) the United Nations Development Pro- gramme; (D) the Global Fund; (E) the World Bank; and (F) the Roll Back Malaria Partnership; (3) program delivery and efforts to lift bar- riers that would impede effective and com- prehensive malaria control programs; and (4) partner or recipient country governments and national entities including universities and civil society organizations (including faith- and community-based organizations). (f) Research To carry out this section, the Malaria Coordi- nator, in accordance with section 2151b–4 of this title, shall ensure that operations and imple- mentation research conducted under this chap- ter will closely complement the clinical and pro- gram research being undertaken by the National Institutes of Health. The Centers for Disease Control and Prevention should advise the Ma- laria Coordinator on priorities for operations and implementation research and should be a key implementer of this research. (g) Monitoring To ensure that adequate malaria controls are established and implemented, the Centers for Disease Control and Prevention should advise the Malaria Coordinator on monitoring, surveil- lance, and evaluation activities and be a key im- plementer of such activities under this chapter. Such activities shall complement, rather than duplicate, the work of the World Health Organi- zation. (h) Annual report (1) Submission Not later than 1 year after July 30, 2008, and annually thereafter, the President shall sub- mit a report to the appropriate congressional committees that describes United States as- sistance for the prevention, treatment, con- trol, and elimination of malaria. (2) Contents The report required under paragraph (1) shall describe— Page 1990 TITLE 22—FOREIGN RELATIONS AND INTERCOURSE § 7635 (A) the countries and activities to which malaria resources have been allocated; (B) the number of people reached through malaria assistance programs, including data on children and pregnant women; (C) research efforts to develop new tools to combat malaria, including drugs and vac- cines; (D) the collaboration and coordination of United States antimalarial efforts with the World Health Organization, the Global Fund, the World Bank, other donor governments, major private efforts, and relevant executive agencies; (E) the coordination of United States anti- malarial efforts with the national malarial strategies of other donor or partner govern- ments and major private initiatives; (F) the estimated impact of United States assistance on childhood mortality and mor- bidity from malaria; (G) the coordination of antimalarial ef- forts with broader health and development programs; and (H) the constraints on implementation of programs posed by health workforce short- ages or capacities; and (I) the number of personnel trained as health workers and the training levels achieved. (Pub. L. 108–25, title III, § 304, May 27, 2003, 117 Stat. 737; Pub. L. 110–293, title III, § 304, July 30, 2008, 122 Stat. 2961.) Editorial Notes REFERENCES IN TEXT This chapter, referred to in subsecs. (f) and (g), was in the original ‘‘this Act’’, meaning Pub. L. 108–25, May 27, 2003, 117 Stat. 711, which is classified principally to this chapter. For complete classification of this Act to the Code, see Short Title note set out under section 7601 of this title and Tables. AMENDMENTS 2008—Pub. L. 110–293 amended section generally. Prior to amendment, section consisted of subsecs. (a) to (h) relating to a pilot program for the placement of health care professionals in overseas areas severely affected by HIV/AIDS, tuberculosis, and malaria. Executive Documents DELEGATION OF FUNCTIONS For delegation of functions of President under this section, see Ex. Ord. No. 12163, Sept. 29, 1979, 44 F.R. 56673, as amended, set out as a note under section 2381 of this title. § 7635. Report on treatment activities by relevant executive branch agencies (a) In general Not later than 15 months after May 27, 2003, the President shall submit to appropriate con- gressional committees a report on the programs and activities of the relevant executive branch agencies that are directed to the treatment of individuals in foreign countries infected with HIV or living with AIDS. (b) Report elements The report shall include— (1) a description of the activities of relevant executive branch agencies with respect to— (A) the treatment of opportunistic infec- tions; (B) the use of antiretrovirals; (C) the status of research into successful treatment protocols for individuals in the developing world; (D) technical assistance and training of local health care workers (in countries af- fected by the pandemic) to administer antiretrovirals, manage side effects, and monitor patients’ viral loads and immune status; (E) the status of strategies to promote sus- tainability of HIV/AIDS pharmaceuticals (including antiretrovirals) and the effects of drug resistance on HIV/AIDS patients; and (F) the status of appropriate law enforce- ment officials working to ensure that HIV/ AIDS pharmaceutical treatment is not di- minished through illegal counterfeiting and black market sales of such pharmaceuticals; (2) information on existing pilot projects, in- cluding a discussion of why a given population was selected, the number of people treated, the cost of treatment, the mechanisms estab- lished to ensure that treatment is being ad- ministered effectively and safely, and plans for scaling up pilot projects (including projected timelines and required resources); and (3) an explanation of how those activities re- late to efforts to prevent the transmission of the HIV infection. (Pub. L. 108–25, title III, § 305, May 27, 2003, 117 Stat. 739.) Executive Documents DELEGATION OF FUNCTIONS For delegation of functions of President under this section, see Ex. Ord. No. 12163, Sept. 29, 1979, 44 F.R. 56673, as amended, set out as a note under section 2381 of this title, and Memorandum of President of Feb. 23, 2004, 69 F.R. 9509, set out as a note under section 7611 of this title. § 7636. Study on illegal diversions of prescription drugs Not later than 180 days after May 27, 2003, the Secretary of Health and Human Services, in co- ordination with other agencies, shall submit a report to the Congress that includes the fol- lowing: (1) A thorough accounting of evidence indi- cating illegal diversion into the United States of prescription drugs donated or sold for hu- manitarian efforts, and an estimate of the ex- tent of such diversion. (2) Recommendations to increase the admin- istrative and enforcement powers of the United States to identify, monitor, and pre- vent the illegal diversion into the United States of prescription drugs donated or sold for humanitarian efforts. (3) Recommendations and guidelines to ad- vise and provide technical assistance to devel- oping countries on how to implement a pro- gram that minimizes diversion into the United States of prescription drugs donated or sold for humanitarian efforts.